PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28053220-8	2017	In this study, in vitro inhibition assays using rivaroxaban as the probe substrate demonstrated that both dronedarone and NDBD produced reversible inhibition as well as irreversible mechanism-based inactivation of CYP3A4- and CYP2J2-mediated metabolism of rivaroxaban.	N-desbutyldronedarone	122-126	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	214-220	
26490246-0	2016	Inactivation of Human Cytochrome P450 3A4 and 3A5 by Dronedarone and N-Desbutyl Dronedarone.	N-desbutyldronedarone	69-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	22-41	
26490246-4	2016	We demonstrated for the first time that both dronedarone and its main metabolite N-desbutyl dronedarone (NDBD) inactivate CYP3A4 and CYP3A5 in a time-, concentration-, and NADPH-dependent manner.	N-desbutyldronedarone	81-103	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	122-128	
26490246-4	2016	We demonstrated for the first time that both dronedarone and its main metabolite N-desbutyl dronedarone (NDBD) inactivate CYP3A4 and CYP3A5 in a time-, concentration-, and NADPH-dependent manner.	N-desbutyldronedarone	105-109	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	122-128	
26490246-5	2016	For the inactivation of CYP3A4, the inactivator concentration at the half-maximum rate of inactivation and inactivation rate constant at an infinite inactivator concentration are 0.87 microM and 0.039 minute(-1), respectively, for dronedarone, and 6.24 microM and 0.099 minute(-1), respectively, for NDBD.	N-desbutyldronedarone	300-304	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-30	
26490246-7	2016	The partition ratios for the inactivation of CYP3A4 and CYP3A5 by dronedarone are 51.1 and 32.2, and the partition ratios for the inactivation of CYP3A4 and CYP3A5 by NDBD are 35.3 and 36.6.	N-desbutyldronedarone	167-171	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51	
26490246-7	2016	The partition ratios for the inactivation of CYP3A4 and CYP3A5 by dronedarone are 51.1 and 32.2, and the partition ratios for the inactivation of CYP3A4 and CYP3A5 by NDBD are 35.3 and 36.6.	N-desbutyldronedarone	167-171	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	146-152	
26490246-8	2016	Testosterone protected both CYP3A4 and CYP3A5 from inactivation by dronedarone and NDBD.	N-desbutyldronedarone	83-87	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-34	
28053220-4	2017	Amiodarone, dronedarone, and their major metabolites, N-desethylamiodarone (NDEA) and N-desbutyldronedarone (NDBD), demonstrate inhibitory effects on CYP3A4 and CYP2J2 with U.S. Food and Drug Administration-recommended probe substrates.	N-desbutyldronedarone	86-107	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	150-156	
28053220-4	2017	Amiodarone, dronedarone, and their major metabolites, N-desethylamiodarone (NDEA) and N-desbutyldronedarone (NDBD), demonstrate inhibitory effects on CYP3A4 and CYP2J2 with U.S. Food and Drug Administration-recommended probe substrates.	N-desbutyldronedarone	109-113	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	150-156	
26490246-10	2016	MBI of CYP3A4 and CYP3A5 was further supported by the discovery of glutathione adducts derived from the quinone oxime intermediates of dronedarone and NDBD.	N-desbutyldronedarone	151-155	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	7-13	
26490246-11	2016	In conclusion, dronedarone and NDBD inactivate CYP3A4 and CYP3A5 via unique dual mechanisms of MBI and formation of the metabolite-intermediate complex.	N-desbutyldronedarone	31-35	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	47-53